• Allapinin (Lappaconitine hydrobromide) 25mg 30 tablets

Expiration date: 03/2025

Composition and form of issue:

Tablets, 1 tablet contains:

allapinin 25 mg

excipients: sugar, potato starch, calcium stearate 

in a contour acheikova packing 10 or 30 PCs per cartons 3 or 1 pack.

Description of dosage form:

The tabs are round, biconvex, white.

Characteristic:

The hydrobromide of the alkaloid lappaconitine (with a mixture of related alkaloids), derived from the herb Aconite Belousovo Aconitum leucostomum Worosch. and rhizomes with the roots of the Northern fighter (high fighter) Aconitum eptentrionale Koelle (A. excelsum Reichenb.) this. Buttercup family (Ranunculaceae).

Pharmacokinetics:

Bioavailability is 40%, has the effect of the first passage through the liver, penetrates through the BBB.

T1/2 is 1-1 / 2 hours Excreted by the kidneys possibly lengthening T1/2 the long-term use in chronic renal failure — in 2-3 times, cirrhosis of the liver — in 3-10 times. VD ingestion — 690 l.

Description of pharmacological action:

Antiarrhythmic drug class I, blocks the fast sodium channels of the membranes of cardiomyocytes. Causes slowing of AV and intraventricular conduction, shortens the effective and functional refractory period of the Atria, AV node, bundle of gissa and Purkinje fibers, do not affect the duration of the QT interval, conduction at the AV node in the antegrade direction, heart rate and blood pressure, myocardial contractility (in the initial absence of the phenomena heart failure). Does not depress the automatism of the sinus node. It does not have a negative inotropic and hypotensive effect. It has a moderate antispasmodic, local anesthetic and sedative effect.

When administered, the effect develops after 40-60 minutes, reaches its maximum after 4-5 hours and lasts for 8 hours or more.

Indications:

  • supraventricular and ventricular premature beats
  • paroxysms and flicker atrial flutter
  • paroxysmal supraventricular tachycardia (including wolf-Parkinson-white syndrome) (WPW)
  • paroxysmal ventricular tachycardia (in the absence of organic heart lesions).

Contraindications:

  • hypersensitivity to the drug
  • sinoatrial blockade
  • AV blockade II and III extent (without pacemaker)
  • cardiogenic shock
  • blockade of the right leg of a bunch of GIS, combined with the blockade of one of the branches of the left leg
  • blockade of intragastric conductivity
  • severe hypotension
  • chronic heart failure
  • expressed hypertrophy of the left ventricular myocardium (&ge1. 4 cm)
  • the presence of postinfarction cardiosclerosis
  • expressed violations of liver or kidney function
  • pregnancy
  • lactation
  • the age of 18 years (efficacy and safety not established).

With caution:

  • AV blockade of I degree
  • violation of intraventricular conduction
  • sinus node weakness syndrome
  • bradycardia
  • severe circulatory disorders
  • glaucoma
  • prostatic hypertrophy
  • violation of conductivity on Purkinje fibers
  • blockade of one of the legs of a bunch of GIS
  • violation of electrolyte metabolism (hypokalemia, hyperkalemia, hypomagnesemia).

Side effect:

Dizziness, headache, feeling of heaviness in the head, hyperemia of the face, ataxia, diplopia allergic reactions. With prolonged use is possible the appearance of sinus tachycardia.

Possible violations of intraventricular and AV conduction, arrhythmogenic effect, changes in the ECG-extension of the PQ interval, extension of the QRS complex.

Drug interaction:

Inducers of microsomal liver enzymes reduce efficiency, increase the risk of toxic effects.

Antiarrhythmic agents of other classes increase the risk of arrhythmogenic action. Enhances the effect of non-depolarizing muscle relaxants.

Dosage and administration:

Inside, drinking water.

By 25 mg (1 table.) 3 times a day in the absence of effect-50 mg (2 table.) 3-4 times a day. The highest single dose-0, 15 g, daily-0, 3 g. The beginning of action after a single reception - through 40-60 minutes, the total duration of action-over 8 hours.

In severe chronic renal failure requires a reduction in the dose.

The duration of treatment is determined by the doctor.

Special instruction:

When headache, dizziness, diplopia should reduce the dose. With the appearance of sinus tachycardia on the background of long-term administration of the drug shows beta-blockers (small doses).

Allapinin
(Lappaconitine
hydrobromide)
25mg
30
tablets

  • $15.00